boosts US team following FDA clearances

Radiology AI company has appointed healthcare technology executives Lakshmi Gudapakkam as chief executive officer and clinical strategist Dr Rick Abramson as chief medical officer. With the new appointments, expects to further accelerate its global market presence and entry into the US market following recent FDA approvals for part of its comprehensive radiology AI product.

The appointment of Gudapakkam will help accelerate expansion plans globally and into the US along with the development of new AI radiology tools. He brings a wealth of health technology expertise, serving in senior global technology and business leadership roles for more than 20 years at GE Healthcare and Philips Healthcare and for the last four years with Quest Diagnostics. At Philips Healthcare, he oversaw breakthrough products in CT and advanced visualisation imaging. Later, Gudapakkam moved into global business leadership roles, building up Philips Healthcare’s footprint across China, India and the rest of Asia.

Dr Abramson will be responsible for guiding the company’s clinical roadmap for international expansion. A US-based physician leader and board-certified radiologist, Dr Abramson brings more than 25 years of experience in healthcare including prior roles in clinical practice, academic research, policy development and management. Previously corporate vice president over the radiology service line at HCA Healthcare, Dr Abramson led enterprise strategic development for radiology and AI across HCA’s network of 185 hospitals in the US and UK. In his new role, Dr Abramson will help advance stakeholder partnerships with healthcare providers, technology developers and regulatory bodies across the world. combines AI with clinical expertise to bring comprehensive AI products to market quickly, with state-of-the-art performance. Formed in 2019 as a joint venture between healthcare AI platform and I-MED Radiology Network, Australia’s largest diagnostic imaging network, the company is focused on rapidly developing and commercialising comprehensive AI products to advance patient care. says its products have been used to help more than one million patients since launch. Annalise Enterprise CXR, a comprehensive decision-support AI solution for chest x-rays, is already in clinical use at more than 400 sites in Australia and the UK and accessible by one in four Australian radiologists. A recent peer-reviewed diagnostic accuracy study published in The Lancet Digital Health found Annalise Enterprise CXR improved radiologists’ diagnostic accuracy across 102 chest x-ray findings.

The company has clearance for clinical use for Annalise Enterprise CXR in the UK, Europe, Australia, south-east Asia and New Zealand and is expanding its products to new geographies. Earlier this year, Annalise Enterprise CXR received CADt FDA clearance for use in triage and notification of pneumothorax and tension pneumothorax on chest x-rays.

Picture: Lakshmi Gudapakkam and Dr Rick Abramson.

Published on page 25 of the September 2022 issue of RAD Magazine.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more